Dentsu Inc. Ventures, a venture fund managed by Dentsu Inc., has invested in Q, Inc., a U.S. company developing healthcare solutions that analyze molecular-level bio data at home.

On December 25, Dentsu Inc. Ventures, the corporate venture capital fund managed by Dentsu Inc., invested in Cue Inc., a U.S. company developing "Cue," a healthcare solution enabling molecular-level bio-data analysis at home.

Dentsu Ventures, established in April this year, aims to realize open innovation within the Dentsu Group through investments in ambitious startups creating unseen futures and collaboration with portfolio companies. It supports businesses and entrepreneurs not only through funding but also by providing solutions and resources unique to the Dentsu Group for tackling challenges. Cue Inc. became its fifth investment.

Cue Inc. develops box-shaped hardware and diagnostic cartridges that simplify molecular-level healthcare data analysis at home, along with a smartphone application to manage the analysis results. By collecting small samples such as saliva, blood, or mucus and inserting color-coded cartridges (specific to each test) into the box-shaped hardware, users can easily analyze factors like vitamin D, testosterone, inflammation, influenza, and pregnancy readiness. Following regulatory approvals in various countries, Q aims for a mid-2016 launch in Europe and Hong Kong, a 2016 launch in the US, and a 2017 launch in Japan. The company also plans to support approximately 20 different test items in the future.

Dentsu Inc. Ventures believes that as interest in health grows, Cue's technology—enabling users to easily analyze their own molecular-level biological information and utilize it for health improvement—will become increasingly important.

Moving forward, the Dentsu Group will support the expansion of Cue's healthcare solution "Cue" and the company's development of new business opportunities.

Details of the "Cue" product and an overview of Cue and Dentsu Ventures are as follows.

<Cue Inc. Overview>

Company Name: Cue Inc

Headquarters: San Diego, California, USA

Representative: Ayub Khattak (CEO)

Number of Employees: 30

Business Description: Provides solutions enabling molecular-level healthcare data analysis at home

URL: http://cue.me/ <OVERVIEW of Dentsu Ventures> Name: Dentsu Ventures Global Fund I Total Fund Size: ¥5 billion Fund Formation Date: April 2015 Operation Period: Planned for 7 years until March 2022 Investment Regions: Primarily overseas regions including Europe, the US, and Asia, with global investment Investment Stage: Primarily seed/early stage, while also including mid/late stage—a broad, balanced investment approach Investment Areas: (1) Areas with the potential to transform broad marketing/communication businesses 　　　　　　　(2) Innovative, high-potential new domains not fitting the above criteria URL: http://dentsu-v.com/ Dentsu Inc. News Releasehttp://www.dentsu.co.jp/news/release/2015/1225-008611.html &nbsp;

&nbsp;